Bill Ackman

Bill Ackman

Last Update: 11-23-2015

Number of Stocks: 8
Number of New Stocks: 1

Total Value: $13,950 Mil
Q/Q Turnover: 13%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

Bill Ackman Watch

  • Mondelez Is Cheap Under $45

    Bill Ackman - Mondelez Is Cheap Under $45

    If anything, Bill Ackman (Trades, Portfolio) agrees that buying Mondelez (NASDAQ:MDLZ) stock between $40.81 and $46.81 over the last quarter was a bargain. The guru investor had this to say in September:


  • Hillary and Citron Research Do Not Scare Goldfarb and Poppe

    Warren Buffett,Ruane Cunniff,Bill Ackman - Hillary And Citron Research Do Not Scare Goldfarb And Poppe

    Ruane Cuniff & Goldfarb was founded by William Ruane (1925- 2005). Warren Buffett (Trades, Portfolio) always spoke highly of Ruane, both attended the same class by Graham, but the firm is also considered of guru level because of its long-term track record and strong value investing fundamental approach. The firm is best known for its Sequoia Fund Inc., which has trounced the Standard & Poor's 500 since inception in 1970. One thing to keep in mind is that Ruane Cunniff (Trades, Portfolio) focused on the intrinsic value of business, but they are committed to the long term and will buy a stock and hold it even through periods of modest overvaluation. The fund is managed by Robert Goldfarb, 67, and David Poppe, 47.

    Recently the firm has been criticized over its giant position in Valeant Pharmaceuticals (NYSE:VRX), which takes up 31% of the firm’s portfolio. Valeant recently declined sharply after Citron Research and Bronte Capital both published research material showing possible questionable business practices by the pharmaceutical company.


  • Coke in the Crosshairs: Bill Ackman’s Next Target?

    Bill Ackman,Carl Icahn,Warren Buffett,Charlie Mung - Coke In The Crosshairs: Bill Ackman’s Next Target?

    Bill Ackman is known for having something of a nasty temper – and not responding well to criticism. His brawl with fellow hedgie Carl Icahn on live TV two years ago over Herbalife (HLF) might be the most high-profile fight among financiers in history.

    Well, now Ackman is trading barbs with another long-term legend of the industry, Warren Buffett’s Berkshire Hathaway (BRK.A) partner Charlie Munger (Trades, Portfolio), over their respective positions in Valeant Pharmaceuticals (VRX) and Coca-Cola (KO).


  • Pershing Square 3rd Quarter Investor Call

  • Notes on the 3Q 2015 Pershing Square Quarterly Conference Call

    Bill Ackman - Notes On The 3Q 2015 Pershing Square Quarterly Conference Call

    Bill Ackman (Trades, Portfolio) of Pershing Square has been extremely successful with his concentrated activist strategy but as of late has hit something of a speedbump. First Hillary Clinton tweeted about drug pricing getting out of hand which hurt his healthcore holdings. Subsequently, Citron Research published an unfavorable research report on Pershing’s largest holding Valeant Pharmaceuticals (NYSE:VRX). As Citron is considered a rather sharp short seller with a good track record the market took note and Valeant sold off sharply. Valeant continues to be under intense scrutiny and has severed all ties with the Philidor specialty pharmacy.

    To say the least, the Pershing Square quarterly conference call was highly anticipated. I have taken notes on the companies that are discussed on the call and the key takeaways for each company discussed. Ackman and his analysts talked about each holding in order of size of the position, but I will start with Valeant:


  • Market Posts Best October Returns in 4 Years

    Bill Ackman, David Einhorn, Donald Yackman, Daniel - Market Posts Best October Returns In 4 Years

    October is not known as a month for strong market returns, but investors got a reprieve last month as returns were some of the best in the past four years.

    The DJIA gained 8.5%, its best performance since October 2011, while the S&P 500 was up 8.3%, the best monthly return in four years. Small-caps lagged behind, but the Russell 2000 still posted a 5.9% gain for the month.


  • My Indirect Experiences With Valeant Pharmaceuticals

    Bill Ackman,Jeff Ubben,Lou Simpson,Wallace Weitz,C - My Indirect Experiences With Valeant Pharmaceuticals

    Valeant Pharmaceuticals International Inc. (NYSE:VRX) has been a hot topic recently with high-profile investors and short sellers both involved in one of the most interesting dramas ever. Valeant's shareholder base includes some of the most admired investors including Bill Ackman (Trades, Portfolio), Jeff Ubben (Trades, Portfolio), the Sequoia Fund, Lou Simpson (Trades, Portfolio) and Wallace Weitz. It is really fascinating to watch on the sideline as the events unfold.

    This is not intended to add any personal thoughts on whether or not Valeant’s business is legitimate or not as I don’t know enough about the business to have useful insights. But over the past year, I’ve been exposed to Valeant in a few incidents, which I think may be worthwhile to share with the readers.


  • Bill Ackman Addresses His Valeant Position

  • Does M&A Still Have a Future in Big Pharma?

    Bill Ackman - Does M&A Still Have A Future In Big Pharma?

    It’s been a catastrophic week for Valeant (NYSE:VRX). In the past few days, the $40 billion serial acquirer has been slashed to ribbons by a leading presidential candidate, seen its stock plunge by nearly half and been likened to Enron by a leading short-selling firm.

    Now, Valeant is facing a set of menacing questions concerning its corporate growth strategy. Fund managers can’t get rid of bonds quick enough, and investors seem to think the firm’s disastrous falter has proven beyond a reasonable doubt that M&A should no longer have a leading role in the pharmaceuticals industry.


  • Citron Founder on Valeant: Given Subpoena Power, Could Prove Claims

    Bill Ackman - Citron Founder On Valeant: Given Subpoena Power, Could Prove Claims Andrew Left, founder at Citron Research, the stock-commentary site that raised questions about Valeant Pharmaceuticals that led to a stock rout spoke to Bloomberg Television today. He discussed his allegations against Valeant (NYSE:VRX) and Philidor, Bill Ackman (Trades, Portfolio), and the stock reaction.

    On whether he has proven the claims he's made, Left said: "It's also not my job to actually prove it. I promise, if you gave me subpoena power, six months and unlimited resources, I would be no doubt be able to prove it." He added: "What they are doing right now appears to be illegal."

  • Ackman, Paulson Funds Hit by Scathing Short-Seller Report on Valeant

    Bill Ackman,John Paulson - Ackman, Paulson Funds Hit By Scathing Short-Seller Report On Valeant

    Investors like Bill Ackman (Trades, Portfolio), Ruane Cunniff (Trades, Portfolio) and John Paulson (Trades, Portfolio) took hits to their portfolio today after a company published a damning reporting on one of their key holdings, Valeant Pharmaceutical (NYSE:VRX). The company’s shares plunged as much as 33% on Wednesday, after providing the investors solid paper gains this year.


  • Loeb, Ackman's Portfolios Post Losses for Year as Top Bets Fall

    Daniel Loeb,Bill Ackman - Loeb, Ackman's Portfolios Post Losses For Year As Top Bets Fall

    During a volatile market during the third quarter, several prominent hedge funds saw their returns decline.

    Pershing Square, Bill Ackman (Trades, Portfolio)’s fund, fell 12.5% in September, bringing its total third quarter decline to 15.3%. This compares to the HFRX Equity Hedge Index low of 2.08% for September. It also declined 12.6% for the first three quarters of the year, compared to the index decline of 3.13%. The first two weeks of the fourth quarter fared better, up 3.6%, but the total year-to-date decline still languished at 9.4%.


  • Who to Side With on General Electric: Peltz or Ackman?

    Warren Buffett,Bill Ackman - Who To Side With On General Electric: Peltz Or Ackman?

    General Electric (NYSE:GE) can be divided into seven separate businesses in its industrial segment: power and water, oil and gas, energy management, aviation, health care, transportation and lighting. The company is in the process of downsizing its finance division, and the latest news is it sold a considerable chunk of $32 billion in book value to Wells Fargo (NYSE:WFC). The company wants to concentrate on the industrial segment and sell off additional parts of the remaining finance portfolio until the end of 2016.

    Notably Nelson Peltz, through his Trian Fund, has taken a $2.5 billion position in General Electric. Peltz is apparently enamored with the company’s industrial businesses with lots of recurring predictable revenue streams at solid margins. Peltz is likely to pressure management, if needed, to operate even more efficiently throughout the organization and cut any unnecessary fat.


  • GE Has Been an Absolute Failure in Allocating Capital – Bill Ackman

    Bill Ackman - GE Has Been An Absolute Failure In Allocating Capital – Bill Ackman

    Bill Ackman (Trades, Portfolio) isn't too worried about hurting feelings at General Electric (NYSE:GE).

    When asked about the giant American company Ackman says that it has a miserable track record of allocating capital. Ackman believes ventures like NBC (NBC) and oil and gas have cost GE shareholders a lot of money over the years.


  • A Half Hour With Bill Ackman – Why Are The Markets So Volatile?

    Bill Ackman - A Half Hour With Bill Ackman – Why Are The Markets So Volatile?

    Why have the markets been so volatile?

    Bill Ackman (Trades, Portfolio) points to the fact that a huge amount of money is traded based on nothing that has to do with long-term company fundamentals.


  • What Top Value Investors Think About Fed's Interest Rate Decision

    Bill Nygren,Bill Ackman,Brian Rogers,Mario Gabelli - What Top Value Investors Think About Fed's Interest Rate Decision

    Market volatility has increased as the Federal Reserve’s decision on whether to raise interest rates for the first time in almost a decade approaches this week. Many value investors, who typically remain relatively impassive in the face of market vagaries, nevertheless have been addressing the noteworthy event.

    The following is a collection of guru interviews and shareholder letter excerpts that discuss how they view interest rates, what they expect the outcome of a Fed move to be and whether the macro decision will change their investing in any way.


  • Bill Ackman Comments on Fannie Mae, Freddie Mac

    Fannie Mae (FNMA) / Freddie Mac (FMCC)

    Fannie and Freddie reported another strong quarter. These results further corroborate our thesis that both entities could recapitalize and safely exit conservatorship if the Net Worth Sweep (the U.S. Government’s expropriation of each quarter’s net worth by extraordinary dividends) is eliminated. During the quarter, there were a number of positive legal developments in the shareholder litigation against the U.S. Government expropriation.


  • Bill Ackman Comments on Nomad Foods Ltd.

    Nomad Foods Ltd. (NHL)

    Nomad is a Special Purpose Acquisition Company (“SPAC”) sponsored by Martin Franklin and Noam Gottesman. The SPAC originally raised $500 million in the spring of 2014. In the spring of 2015, Martin approached us with an opportunity to become an anchor shareholder in Nomad. At that time, Nomad was contemplating a $2.8 billion acquisition of Iglo Group. Given the size of the acquisition, it needed to raise substantial additional equity.


  • Bill Ackman Comments on Herbalife Short

    Herbalife (NYSE:HLF) Short

    Despite the substantial increase in HLF’s share price year to date, we remain confident that HLF is an unlawful pyramid scheme that will eventually be shut down by regulators or collapse on its own.


  • Bill Ackman Comments on Howard Hughes Corp

    Howard Hughes Corp. (NYSE:HHC)

    HHC reported mixed results for the quarter with strong NOI growth from operating assets, continued sales of condominiums in Hawaii at record-setting prices, and reduced land sales at the company’s Houston master planned communities (MPCs) due to lower demand as a result of uncertainty in the energy business.


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)